Quanterix Corporation has entered into a merger agreement with Akoya Biosciences, where Akoya will become a wholly owned subsidiary of Quanterix, with an exchange ratio of 0.318 shares of Quanterix for each share of Akoya. The merger is subject to various approvals and conditions, including stockholder votes and regulatory clearances, with a completion target by July 2025.